Competitive: Biofidelity: Biofidelity is a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we Cambridge, United Kingdom

Notice NOT-CA-25-005 from the NIH Guide for Grants and Contracts

£35,857 - £38,551. A Civil Service Pension with an employer contribution of 28.97%.: APHA: You will work on several high-profile projects aimed at defining, characterising, and controlling these pathogens globally..... New Haw, South East England, KT15 3NB

Funding Opportunity RFA-CA-25-010 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites proposals for Research Projects to advance the science of scale-up and sustainment of tobacco use treatment (TUT) for cancer survivors. Each Research Project will propose a trial to test implementation strategies to equitably and effectively scale-up and sustain the delivery of TUT to a large number of diverse clinical care delivery settings and cancer survivor populations, with an emphasis on cancer survivor populations experiencing health inequities.

Notice NOT-DE-25-040 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-001 from the NIH Guide for Grants and Contracts

Notice NOT-HS-24-027 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-050 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required.

Funding Opportunity PAR-25-055 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Notice NOT-AG-24-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-020 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.

Competitive: Illumina, Inc.: What if the work you did every day could impact the lives of people you know? Or all of humanity? At Illumina, we are expanding access to genomic tec Cambridge, United Kingdom

Competitive: Illumina, Inc.: What if the work you did every day could impact the lives of people you know? Or all of humanity? At Illumina, we are expanding access to genomic tec Cambridge, United Kingdom

Competitive: Illumina, Inc.: What if the work you did every day could impact the lives of people you know? Or all of humanity? At Illumina, we are expanding access to genomic tec Cambridge, United Kingdom

Competitive: Illumina, Inc.: What if the work you did every day could impact the lives of people you know? Or all of humanity? At Illumina, we are expanding access to genomic tec Cambridge, United Kingdom

Funding Opportunity RFA-CA-25-009 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to advance the science of scale-up and sustainment of lung cancer screening (LCS) for populations at high risk for lung cancer. This NOFO will support studies that will identify the most effective implementation strategies for scaling-up and sustaining the delivery of LCS across a range of clinical care settings and diverse populations at high risk for lung cancer. This NOFO will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support preparatory activities for the scale-up and sustainment trial. The UH3 phase will support the scale-up and sustainment trial.

Notice NOT-DA-24-046 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-109 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-25-080 from the NIH Guide for Grants and Contracts. The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.